Obsidian Therapeutics is targeting oncologic indications with cell and gene therapies developed with the use of their cytoDRIVE platform. Their lead program, cytoTIL15, is a tumor-infiltrating lymphocyte (TIL) therapy in investigational new drug (IND)-enabling studies for melanoma as well as preclinical studies for head and neck squamous cell carcinomas and discovery phases for other oncologic […]

Imagine surviving cancer and then getting a new chronic disease as a side effect of treatment. That’s reality for cancer survivors who develop the limb-swelling complication lymphedema, which is caused by a buildup of lymphatic fluid. But as medical device maker ImpediMed points out in its first major consumer-facing campaign, testing and early detection can […]

Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among Parkinson’s disease patients in a Phase 2a clinical trial. Annovis Bio, the company developing ANVS401, is now planning to meet with the U.S. Food and Drug Administration (FDA) to discuss possibly initiating larger Phase 3 studies. “We are thrilled by these improvements in motor […]